Antibodies, Monoclonal, Murine-Derived
-
Subject Areas on Research
-
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.
-
A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia.
-
A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
-
A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma.
-
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.
-
Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT.
-
Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report.
-
Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts.
-
Antiviral antibodies are necessary for control of simian immunodeficiency virus replication.
-
Association of serum B-cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients.
-
B cell-directed therapies for autoimmune disease and correlates of disease response and relapse.
-
B cells in chronic graft-versus-host disease.
-
B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions.
-
B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody.
-
B-lymphocyte contributions to human autoimmune disease.
-
CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells.
-
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.
-
Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab.
-
Cellular targeting in autoimmunity.
-
Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712.
-
Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis.
-
Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.
-
Clinical spectrum and prognosis of follicular lymphoma with blastoid transformation: case series and a review of the literature.
-
Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas.
-
Defining Potential Vaccine Targets of Haemophilus ducreyi Trimeric Autotransporter Adhesin DsrA.
-
Designs for randomized phase II clinical trials with two treatment arms.
-
Differential effects of donor-specific alloantibody.
-
Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation.
-
Effect of B-cell depletion on viral replication and clinical outcome of simian immunodeficiency virus infection in a natural host.
-
Efficacy of remission-induction regimens for ANCA-associated vasculitis.
-
Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma.
-
Good and bad memories following rituximab therapy.
-
HIV-1 antibodies and vaccine antigen selectively interact with lipid domains.
-
Hairy cell leukemia: an elusive but treatable disease.
-
Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab).
-
Hepatitis C virus-related cryoglobulinemic vasculitis: emerging trends in therapy.
-
How I treat thrombocytopenia in pregnancy.
-
Identification of compounds that enhance the anti-lymphoma activity of rituximab using flow cytometric high-content screening.
-
Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.
-
Immunosuppressive therapies in myasthenia gravis.
-
Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging.
-
Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002.
-
Improving outcomes in advanced DLBCL: systemic approaches and radiotherapy.
-
Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.
-
Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study.
-
Limited ability of humoral immune responses in control of viremia during infection with SIVsmmD215 strain.
-
Merkel cell carcinoma with partial B-cell blastic immunophenotype: a potential mimic of cutaneous richter transformation in a patient with chronic lymphocytic lymphoma.
-
Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults.
-
New insights and therapeutics for immune-mediated thrombocytopenia.
-
Non-Hodgkin's lymphomas, version 2.2014.
-
Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).
-
Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.
-
Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis.
-
Persistence and selection of an expanded B-cell clone in the setting of rituximab therapy for Sjögren's syndrome.
-
Persistent antibody depletion after rituximab in three children with autoimmune cytopenias.
-
Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response.
-
Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma.
-
Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia.
-
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.
-
Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy.
-
Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis.
-
Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment.
-
Protein modification by deamidation indicates variations in joint extracellular matrix turnover.
-
Rapid identification of monospecific monoclonal antibodies using a human proteome microarray.
-
Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease.
-
Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice.
-
Relapse of thrombotic thrombocytopenic purpura: is it a continuum of disease?
-
Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
-
Rituximab decreases without preference all subclasses of IgG anti-BP180 autoantibodies in refractory bullous pemphigoid (BP).
-
Rituximab for follicular lymphoma: watch and wait, watch and worry, or watch and live?
-
Rituximab for successful management of probable pediatric catastrophic antiphospholipid syndrome.
-
Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.
-
Rituximab in lymphocyte predominance Hodgkin's disease: a case series.
-
Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial.
-
Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.
-
Rituximab therapy for primary Sjögren's syndrome: an open-label clinical trial and mechanistic analysis.
-
Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
-
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
-
Rituximab-associated progressive multifocal leukoencephalopathy after lung transplantation.
-
Sequence intrinsic somatic mutation mechanisms contribute to affinity maturation of VRC01-class HIV-1 broadly neutralizing antibodies.
-
Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis.
-
Small lymphocytic lymphoma presenting as a paraneoplastic syndrome with acute central nervous system demyelination.
-
Stromal gene signatures in large-B-cell lymphomas.
-
Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab).
-
Suppression of adaptive immune responses during primary SIV infection of sabaeus African green monkeys delays partial containment of viremia but does not induce disease.
-
Targeted therapies for cancer 2004.
-
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review.
-
Treatment options for newly diagnosed patients with chronic lymphocytic leukemia.
-
Unusual clinical and immunologic manifestations of transplacentally acquired maternal T cells in severe combined immunodeficiency.
-
Updated survival analysis of two sequential prospective trials of R-MACLO-IVAM followed by maintenance for newly diagnosed mantle cell lymphoma.
-
Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.
-
[18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy.
-
p53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: a single institutional clinicopathologic study.
-
Keywords of People